Skip to search boxSkip to navigationSkip to main content

The role of GILZ in modulation of adaptive immunity in a murine model of myocardial infarction

*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Myocardial infarction (MI) is associated with intense immune and inflammatory responses which contribute to tissue injury. Increasing evidence indicates that the glucocorticoid-induced leucine zipper (GILZ) protein suppresses immune and inflammatory responses. However, the status of and the role of GILZ in MI are not known. We tested the hypotheses that a) MI reduces cardiac GILZ associated with intense inflammation and cell death and b) intramyocardial GILZ delivery confers cardioprotection in association with increased Tregs and suppression of inflammation. Male Balb/C mice were subjected to MI or sham operation; the infarcted animals were subdivided to receive intramyocardial injections of PBS, GILZ overexpressing cells (GILZ) or their controls expressing the green fluorescent protein (GFP). Three hours after the procedures, hearts were procured for subsequent analyses. MI markedly reduced cardiac GILZ expression accompanied with a) increase in Th-17 cells (i.e., CD3+ CD4+ IL-17+ BNP−) but decrease in Tregs (i.e., CD3+ CD4+ FoxP3+ BNP−), and b) disruption of mitochondrial membrane potential (ψm) associated with significant increases in apoptotic and necrotic cell death. While both GILZ and GFP returned the aforementioned parameters towards those of sham controls, these effects were most marked for mice receiving GILZ. Thus, GILZ markedly reduced Th-17 cells but increased Tregs and the anti-inflammatory cytokine, IL-10 positive cells accompanied with preservation of ψm and prevention of cell death. To our knowledge, this is the first report indicating an important role for GILZ in MI, in part via modulation of adaptive immune response, which raises the prospect of exogenous GILZ delivery as a novel cardioprotective modality.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 408-414 (7 pages)

Journal (Volume, Issue Number)

Experimental and Molecular Pathology (Volume 102, Issue 3)

Publication milestones

  • Published - 06/01/2017

Publication status

Published - 06/01/2017

ISSN

0014-4800

Publication IDs

  • Scopus: 85019150965
  • PubMed: 28499885

Publication metrics

Metrics

SciVal
FWCI
0.54
SciVal
Author count
6
SciVal
citations
7
SciVal
Paper percentile
68
Fractional count
3
Fractional count
0.50
Fractional count
3
Fractional count
0.50
Fractional count
3
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
12
Captures
14

Funding Details

FunderFunding number
NIA
R01AG046248